ProCE Banner Activity

Cardiologist Perspectives: Key Takeaways From the 2023 Atrial Fibrillation Guideline Updates

Clinical Thought

Read a cardiologist’s perspective on the new 2023 atrial fibrillation guidelines, including strategies for estimating and reducing stroke risk through proper use of anticoagulants, the importance of evidence-based anticoagulant choice and dosing, and mitigating the bleeding risks of therapy.

Released: July 08, 2024

Expiration: July 07, 2025

Share

Faculty

Christopher B. Granger

Christopher B. Granger, MD

Professor of Medicine and of Nursing
Duke University
Durham, North Carolina

Provided by

Provided by Clinical Care Options, LLC in partnership with ProCE, LLC.

ProCE Banner

Supporters

Supported by an education grant from Janssen Biotech, Inc. administered by Janssen Scientific Affairs, LLC.

Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC

Partners

ProCE, LLC

ProCE Banner

Faculty Disclosure

Primary Author

Christopher B. Granger, MD

Professor of Medicine and of Nursing
Duke University
Durham, North Carolina

Christopher B. Granger, MD: consultant/advisor/speaker: AbbVie, Abiomed, Alnylam, Anthos, Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Cardionomic, Cadrenal, CeleCore, Hengrui, Janssen, Medtronic, Merck, Novo Nordisk, Novartis, Pfizer, Philips, REATA, Roche, Veralox; researcher: Alnylam, Boehringer Ingelheim, Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, Philips, Roche.